HEALTH-RELATED QUALITY OF LIFE MEASUREMENT IN ADULTS WITH SICKLE CELL DISEASE IN STEADY STATE: EXPERIENCE OF ONE FRENCH REFERENCE CENTER

Main Article Content

Giovanna Cannas
Solene Poutrel
Emilie Virot
Manon Marie
Alexandre Guilhem
Amal El-Kanouni
Richard Bourgeay
Marie-Grace Mutumwa
Mohamed Elhamri
Arnaud Hot

Keywords

Sickle cell disease; quality of life; RAND 36; SCSES; hydroxurea; complications.

Abstract

Sickle cell disease (SCD) is a genetic disease of public health concern. Adult patients face various disease-related complications, which affect their quality of life (QoL). Few studies have examined relationships between these events and health-related (HR) QoL. We conducted a study of 240 adults with SCD seen in steady state at a routine clinic visit over one year. Two self-administered questionnaires were used to determine patients’ HRQoL: the sickle cell self-efficacy scale (SCSES) and the unspecific SF-36 scoring system evaluating physical and mental components. Factors impacting HRQoL were established using univariate and multivariate regression analyses. Participants had a median age of 28 years (Sex ratio male/female 0.61; 68% SS genotype). Most of them had experienced more than one SCD-related complication and more than one affected organ system. A good correlation was established between the SCD specific and the unspecific scoring systems. Using the SF-36 scoring system, energy/fatigue, general health and pain subscales showed the lowest median scores, while physical functioning had the highest median score. In univariate and multivariate analyses, hospitalization for SCD complications occurring during the last year preceding QoL evaluation was the main feature impacting HRQoL. Good compliance to hydroxyurea (HU) therapy was associated with higher SCSES and higher emotional role functioning scores. Our study confirms substantial impairment of HRQoL in adults with SCD. HRQoL was mainly influenced by the recent occurrence of severe SCD complications.  Our study suggests that a more effective treatment through a better compliance to HU therapy would provide benefit in terms of QoL.

Downloads

Download data is not yet available.


Abstract 48
PDF Downloads 20
Html Downloads 7

References

[1] Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017; 376:1561-73.
[2] Bulgin D, Tanabe P, Jenerette C. Stigma of sickle cell disease: a systematic review. Issues Ment Health Nurs. 2018; 39:675-86.
[3] Edwards R, Telfair J, Cecil H, Lenoci J. Reliability and validity of a self-efficacy instrument specific to sickle cell disease. Behav Res Ther. 2000; 38:951-63.
[4] Molter BL, Abrahamson K. Self-efficacy, transition, and patient outcomes in the sickle cell disease population. Pain Manag Nurs. 2015; 16:418-24.
[5] Barlett R, Ramsay Z, Ali A, Grant J, Rankine-Mullings A, Gordon-Strachan G, Asnani M. Health-related quality of life and neuropathic pain in sickle cell disease in Jamaica. Disability and Health Journal. 2021; 14:101107.
[6] Al Nagshabandi EA, Abdulmutalib IAM. Self-care management and self-efficacy among ault patients with sickle cell disease. Am J Nurs Res. 2019; 7:51-7.
[7] Barakat LP, Patterson CA, Daniel LC, Dampier C. Quality of life among adolescents with sickle cell disease: mediation of pain by internalizing symptoms and parenting stress. Health Qual Life Outcomes. 2008; 6:60.
[8] Brandow AM, Brousseau DC, Pajewski NM, Panepinto JA. Vaso-occlusive painful events in sickle cell disease: impact on child well-being. Pediatr Blood Cancer. 2010; 54: 92-7.
[9] McClish DK, Penberthy LT, Bovbjerg VE, Roberts JD, Aisiku IP, Levenson JL, Roseff SD, Smith WR. Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes. 2005; 3:50.
[10] Panepinto JA, O’Mahar KM, DeBaun MR, Loberiza FR, Scott JP. Health-related quality of life in children with sickle cell disease: child and parent perception. Br J Haematol. 2005; 130:437-44.
[11] Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care. 1992; 30:473-83.
[12] Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The short form health survey (SF-36): translation and validation study of the Iranian version. Qual Life Res. 2005; 14:875-82.
[13] Van der Zee KI, Sanderman R, Heyink J. A comparison of two multidimensional measures of health status: the Nottingham Health Profile and the RAND 36-item health survey 1.0. Qual Life Res. 1996; 5:165-74.
[14] Dampier C, LeBeau P, Rhee S, Lieff S, Kesler K, Ballas S, Rogers Z, Wang W. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011; 86:203-5.
[15] Anie KA, Dasgupta T, Ezenduka P, Anarado A, Emodi I. A cross-cultural study of psychosocial aspects of sickle cell disease in the UK and Nigeria. Psychol Health Med. 2007; 12:299-304.
[16] Adeyemo TA, Ojewunmi OO, Diaku-Akinwumi IN, Ayinde OC, Akanmu AS. Health related quality of life and perception of stigmatization in adolescents living with sickle cell disease in Nigeria: a cross sectional study. Pediatr Blood Cancer. 2015; 62:1245-51.
[17] Amaeshi L, Kalejaiye OO, Ogamba CF, Popoola FA, Adelabu YA, Ikwuegbuenyi CA, Nwankwo IB, Adeniran O, Imeh M, Kehinde MO. Health-related quality of life among patients with sickle cell disease in an adult hematology clinic in a tertiary hospital in Lagos, Nigeria. Cureus. 2022; 14:e21377.
[18] Okany CC, Akinyanju, OO. The influence of socioeconomic status on the severity of sickle cell disease. Afr J Med Sci. 1993; 22:57-60.
[19] Nelson M, Noisette L, Pugh N, Gordeuk V, Hsu LL, Wun T, Shah N, Glassberg J, Kutlar A, Hankins JS, King AA, Brambilla D, Kanter J. The clinical spectrum of HbSC sickle cell disease-not a benign condition. Br J Haematol. 2024; 205:653-63.
[20] Segbefia C, Luchtman-Jones L. Seeing haemoglobin SC: challenging the misperceptions. Br J Haematol. 2024; 205:404-5.
[21] Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, Koshy M, Barton BA, Bonds DR. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006; 4:59.
[22] Kelly MJ, Pennarola BW, Rodday AM, Parsons SK. Health-related quality of life (HRQOL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). Pediatr Blood Cancer. 2012; 59:725-31.
[23] Badawy SM, Thompson AA, Lai J, Penedo FJ, Rychlik K, Liem RI. Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Health Qual Life Outcomes. 2017; 15:136.
[24] Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamine) for sickle cell disease. Cochrane Database Syst Rev. 2017; 4:CD002202.
[25] Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am J Hematol. 2000; 64:26-31.
[26] Kamal S, Naghib MM, Al Zahrani J, Hassan H, Moawad K, Arrahman O. Influence of nutrition on disease severity and health-related quality of life in adults with sickle cell disease: a prospective study. Mediterr J Hematol Infect Dis 2021; 13:e2021007.